Drugs / Neostigmine
Neostigmine
Trials 54
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06351852 | Mar 2022 → Sep 2024 | constipation disorder, neurogenic bowel, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04027972 | Mar 2020 → Dec 2022 | constipation disorder, neurogenic bowel, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03316963 | Nov 2017 → Mar 2019 | — | Emory University | Terminated | No outcome recorded |
| Phase 0 | NCT02370862 | Feb 2013 → Dec 2016 | neurogenic bowel, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04671030 | Jan → Jun 2018 | constipation disorder, neurogenic bowel, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02370433 | Dec 2012 → Jun 2018 | neurogenic bowel, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00779467 | Oct 2008 → Nov 2013 | — | Wake Forest University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03058263 | Oct 2016 → Feb 2017 | — | Indonesia University | Completed | No outcome recorded |
| Phase 1/2 | NCT02279147 | Aug 2014 → Aug 2017 | autoinflammatory syndrome, obstructive jaundice | Wanqing Gu | Unknown | No outcome recorded |
| Phase 25 trials · 2 met primary | ||||||
| Phase 2 | NCT05342818 | Apr → Jul 2022 | gastroparesis | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05116930 | Nov 2021 → Dec 2027 expected | intracranial hypotension | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT04130230 | Mar 2019 → Aug 2021 | infectious disease with sepsis | Mansoura University | Completed | Met primary |
| Phase 2 | NCT02543658 | Sep 2015 → Aug 2017 | acute pancreatitis | The First Affiliated Hospital of Nanchang University | Completed | Met primary |
| Phase 2 | NCT00855283 | Sep 2012 → Jun 2013 | — | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04905953 | Feb 2021 → Feb 2022 | headache disorder | Cairo University | Unknown | No outcome recorded |
| Phase 37 trials · 1 met primary | ||||||
| Phase 3 | NCT06871033 | Jan → Dec 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT04910477 | Jun → Sep 2021 | headache disorder | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT06351995 | Nov 2020 → Oct 2022 overdue | constipation disorder, neurogenic bowel, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04096144 | Oct 2019 → Mar 2020 overdue | — | University of South Florida | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03116997 | Apr 2017 → Mar 2022 | — | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01422304 | Oct 2011 → Sep 2012 | blood coagulation disease, osteoarthritis, hip, osteoarthritis, knee | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00724932 | Jul 2008 → Apr 2009 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 419 trials · 2 met primary · 2 missed | ||||||
| Phase 4 | NCT06685705 | Dec 2024 → Dec 2025 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05985343 | Jan 2024 → May 2025 | abdominal wall malformation, ileus | Clayton Petro | Completed | No outcome recorded |
| Phase 4 | NCT04951726 | Feb 2022 → Aug 2025 | colonic pseudo-obstruction | University of Southern California | Unknown | No outcome recorded |
| Phase 4 | NCT05053594 | Oct 2021 → Feb 2022 | curariform drugs toxicity | Pontifical Catholic University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT05037006 | Oct → Dec 2021 | curariform drugs toxicity | Pontifical Catholic University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT03958201 | May 2019 → Jan 2020 | respiratory paralysis | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT03543826 | May → Nov 2018 | myopathy | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT03210376 | Nov 2017 → Sep 2018 | digestive system cancer, female reproductive organ cancer, male reproductive organ cancer, malignant urinary system neoplasm | M.D. Anderson Cancer Center | Completed | Missed primary |
| Phase 4 | NCT02845375 | Sep 2016 → Sep 2018 | respiratory failure | Leiden University Medical Center | Completed | Missed primary |
| Phase 4 | NCT03420937 | Jun 2016 → Jun 2017 | — | University Hospital Olomouc | Completed | Met primary |
| Phase 4 | NCT02403063 | Sep → Oct 2015 | — | Onze Lieve Vrouw Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02513693 | Jul 2015 → Mar 2016 | — | Palacky University | Unknown | No outcome recorded |
| Phase 4 | NCT02433808 | Apr 2015 → Dec 2016 | — | Endeavor Health | Completed | No outcome recorded |
| Phase 4 | NCT01718236 | Sep 2012 → Jan 2015 | pregnancy disorder | Brno University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01142648 | Apr 2009 → Mar 2010 | — | Tampere University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00745095 | Mar 2009 → Mar 2013 | spinal cord injury | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00895609 | Mar → Aug 2009 | neuromuscular disease | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT00676377 | Aug → Dec 2007 | ileus | Baqiyatallah Medical Sciences University | Completed | Met primary |
| Phase 4 | NCT00001520 | Sep 1996 → Aug 2000 | palsy | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT07692282 | Jul 2026 → Feb 2028 expected | digestive system disorder | Southeast University, China | Not yet recruiting | No outcome recorded |
| — | NCT07524959 | May → Jul 2026 overdue | — | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07253428 | Oct → Dec 2025 overdue | nasal disorder | Ain Shams University | Active not recruiting | No outcome recorded |
| — | NCT06275542 | Apr → Dec 2024 overdue | — | University of Surabaya | Enrolling by invitation | No outcome recorded |
| — | NCT05993390 | Jan 2024 → Aug 2027 expected | — | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT04997759 | Sep 2021 → Aug 2022 | — | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT04873531 | May → Aug 2021 | thyroid gland disorder | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT04544228 | Sep 2020 → Feb 2021 | — | Cairo University | Completed | No outcome recorded |
| — | NCT04048655 | Apr 2020 → Sep 2025 overdue | — | Tampere University Hospital | Active not recruiting | No outcome recorded |
| — | NCT04777383 | Apr 2019 → Oct 2021 | vascular disorder | University Hospital, Linkoeping | Terminated | No outcome recorded |
| — | NCT06055101 | Jan 2019 → Mar 2022 | — | Reham Ali Abdelhaleem Abdelrahman | Completed | No outcome recorded |
| — | NCT01980069 | Nov 2013 → Oct 2014 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT00407290 | Mar → Oct 2006 | pregnancy disorder | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Unknown | No outcome recorded |
| Comparator or background therapy144 trials | ||||||
| Phase 0 | NCT06501352 Comparator | Jan 2023 → Mar 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT03328312 Comparator | Dec 2017 → Mar 2018 | curariform drugs toxicity | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 1 | NCT06787638 Comparator | Jan 2025 → Jan 2026 overdue | — | Aswan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06982092 Comparator | Aug 2024 → Jan 2025 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT03579589 Comparator | Aug 2018 → Dec 2019 | — | Ohio State University | Completed | No outcome recorded |
| Show all 144 trials opens the full record — a long page | ||||||
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 198 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neostigmine | “The administration of acetylcholinesterase inhibiting agents (such as neostigmine) has been used to reverse the muscle paralysis induced by non-depolarizing neuromuscular...” NCT04920682 ↗197“Depending on depth of block (subjectively assessed by TOF response), Neostigmine, Sugammadex, or no reversal drug is used to reverse block prior to extubation.” NCT03543826 ↗ “At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.” NCT05825430 ↗ “Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline” NCT01142648 ↗ “reversal of the patients was done by injection of neostigmine 0.05mg\\ kg and atropine 0.01mg\\kg.” NCT04365686 ↗ “Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg” NCT02213848 ↗ “consists of patients receiving Serratus anterior plane block using Bupivacaine + neostigmine.” NCT05802979 ↗ “Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)” NCT02648503 ↗ “Intranasal Administration of Neostigmine and Glycopyrrolate for Bowel Evacuation” NCT00855283 ↗ “Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine” NCT04347486 ↗ “reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg” NCT04022733 ↗ |
| Known as | Miostin | “Group B - Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.” NCT03328312 ↗ |
| Known as | NEO | “A group of 6 able-bodied healthy volunteers will receive Neostigmine (NEO) and Glycopyrrolate (GLY) intravenously and via 2 methods of Iontophoresis (ION): one-patch and...” NCT04027972 ↗4“Such measures include the administration of neostigmine (NEO), which increases peristaltic contractions in the colon, resulting in predictable bowel evacuations.” NCT02574611 ↗ “This will be followed by a 2 visit- dose titration study of concomitantly administered, transcutaneous neostigmine methylsulfate (NEO) and glycopyrrolate (GLY).” NCT02370433 ↗ “a medication called neostigmine (NEO) combined with a medication called glycopyrrolate (GLY)” NCT02370862 ↗ “0.03mg/kg neostigmine (NEO) and 0.006mg/kg glycopyrrolate (GLY)” NCT04671030 ↗ |
| Known as | Neostigmine Methylsulfate | “This will be followed by a 2 visit- dose titration study of concomitantly administered, transcutaneous neostigmine methylsulfate (NEO) and glycopyrrolate (GLY).” NCT02370433 ↗ |
| Known as | Neostigmine Methylsulphate | “Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.” NCT06493838 ↗ |
| Known as | Stigmosan | “Group B - Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.” NCT03328312 ↗ |
| Action | Inhibit | “inhibits the hydrolysis of acetylcholine by competing with acetylcholine for attachment to acetylcholinesterase” NCT00001520 ↗ |
| Modality | Other / unclassified | “Neostigmine is an anticholinesterase agent” NCT00001520 ↗ |
| Route | Other | “Neostigmine Group : epidural injection of Ropivacaine and Neostigmine” NCT00407290 ↗ |